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Abstract: DNA replication, transcription, and chromosome condensation require enzymes that 
can regulate the topological changes occurring in DNA following these processes.  
Topoisomerases are such enzymes.  These catalyze the cleavage of single-stranded DNA 
(ssDNA) or double-stranded DNA (dsDNA), the passage of DNA through the resulting break, 
and the rejoining of the broken phosphodiester backbone.  Chemical agents able to interfere with 
these enzymes present in the cancer cells have outstanding therapeutic efficacy in human cancer.  
Camptothecin derivatives (acting on type IB topoisomerases) have been shown to stimulate DNA 
cleavage by topoisomerases leading to cell death by apoptosis, but they are not always specific to 
tumor cells; they are also toxic and there’s much resistance to them.  That is why right now there 
is considerable interest in improving the selectivity of these agents by making them sequence 
specific. Another way to improve the therapeutic efficacy of the drugs is inactivation of NF-B 
molecule which is a negative regulator of apoptosis in cancer cells.  There is also considerable 
interest in developing new non-camptothecin drugs that would also inhibit topoisomerases I but 
in a more efficient and less toxic manner. In summary, the topoisomerase inhibitors are effective 
anti-cancer agents to some extent, but the current research focuses on improving their efficacy 
and selectivity and possibly replacing them altogether with better novel topoisomerase I poisons. 
Colorectal and ovarian cancers are two of the most common cancers within the 
population of the United States.  Ovarian cancer is one that begins in the cells that constitute the 
ovaries, including the epithelial cells, germ cells, and the sex cord-stromal cells.  This type of 
cancer accounts for four percent of all cancers among women and ranks fifth as a cause of their 
deaths from cancer.  The American Cancer Society statistics for ovarian cancer estimate that 
there will be 25,400 new cases and 14,300 deaths in 2004 [4].  Colorectal cancer, on the other 
hand, includes cancers of both the large intestine (colon) and the rectum.  This is the second-
leading cause of cancer related deaths in the United States.  Only lung cancer claims more lives.  
Each year, more than 135,000 Americans are diagnosed with colorectal cancer and 56,000 die 
from it [2 ]. 
Over the last several years the structures of topoisomerases, which are very abundant in 
cancer cells, have finally come to light due to new, innovating techniques. These enzymes can 
2change the topological state of DNA by breaking and rejoining DNA strands.  Topoisomerases 
are involved in all aspects of DNA structure and metabolism.  As a result of this essential task,
topoisomerases are necessary for the viability of all organisms and they have become targets for 
topoisomerase inhibitors, which have become widely used in recent times due their efficacy as 
antimicrobial and antitumor agents [1].
Camptothecin topoisomerase I inhibitors form a relatively new class of anticancer drugs.  
They are the only family of topoisomerase I inhibitors in clinical use for the treatment of mainly 
ovarian and colorectal cancers [3]. The parent compound camptothecin (CPT) was discovered 
forty years ago.  It is extracted from the oriental tree Camptotheca acuminate (Nyssaceae 
family). It consists of five rings (A through E), the fifth being a lactone ring.  In the first years 
after the discovery, the drug was highly unmanageable due its severe and unpredictable 
hematological and non-hematological effects.  It was responsible for myelosuppression, diarrhea, 
nausea, vomiting and hemorrhagic cystitis in patients treated with it.  Later, it was discovered 
that these toxic effects were caused by the low water solubility of the drug.  During 1980s the 
interest in CPTs increased because its mechanism of action was better understood.  Various CPT 
derivatives have been developed with modifications of rings A and B.  This increased their water 
solubility and they have been approved to treat colorectal and ovarian cancers [8]. The two
discussed here are irinotecan (or CPT-11) and topotecan. However, their toxicity and the tumor 
cells’ increasing resistance to these poisons causes the current clinical experiments to focus on 
improving their efficacy for now but ultimately to develop novel non-camptothecin drugs that 
provide better results and have less adverse effects on patients [13].
Topoisomerases are excellent targets for drug inhibitors so it is necessary that their 
reaction mechanism is known. A property of DNA in all known organisms is the DNA 
3supercoiling, which is the bending and the twisting of the helical DNA. Cellular DNA is coiled 
in the form of a double helix, in which both strands of the DNA coil around and axis. The 
further coiling of that axis upon itself produces DNA supercoiling. Within the cell’s nucleus 
DNA is strained to maintain its supercoiled state.  In almost every instance, the strain is a result 
of an underwinding of the double helix – there are fewer helical turns than expected.  This is a 
deviation from the most stable DNA form and the only way to accommodate this strain is for the 
DNA to supercoil.  A property of DNA that topoisomerases can change is the linking number, 
which can be defined as the number of times one strand of DNA crosses the other.  Negative 
supercoiling (induced by underwinding of the double helix) reduces the linking number of the 
relaxed DNA strand.  Positive supercoiling on the other hand, which is induced by overwinding, 
increases the linking number [3].  While cells stably maintain their genomic DNA with negative 
supercoiling, essential cellular activities such as transcription and replication introduce additional 
supercoils and topological distortions in DNA.  Since DNA supercoiling and topology occupy a 
central position in cellular regulation, the control of DNA supercoiling is an important 
pharmaceutical target.  All topoisomerases reduce the supercoiling and change the linking 
number by cleaving DNA through the formation of a transient covalent phosphotyrosine 
enzyme/DNA complex.  Topoisomerases are divided into type I and type II enzymes, which 
respectively introduce single-stranded and double-stranded breaks in DNA [10]. Eukaryotic 
cells have both type I and type II topoisomerases.  This research paper will focus on the type IB
topoisomerases which are the targets of camptothecins and generally relax DNA by removing 
negative supercoils (increasing linking number). The mechanism and structure of type I 
eukaryotic topoisomerases is similar to that found in prokaryotes [3].
4Topoisomerase type I is a protein of the metaphase chromosome scaffold-like structure.  
Certain regions of DNA are associated with the nuclear scaffold.  The regions of DNA associated 
with the scaffold are separated by loops of DNA with 20,000 to 100,000 base pairs.  The scaffold 
itself contains several proteins and one of those is topoisomerase I.  The enzyme is extremely 
important in the assembly of chromatin so it is abundant in rapidly dividing cells such as cancer 
cells.  Thus, any inhibitors of this enzyme will kill these cells.  In the interphase, topoisomerase I 
is bound to the nuclear matrix and so is the DNA replication machinery. This is a very important 
fact that allows the topoisomerase inhibitors to cause lethal lesions in DNA. The nuclear matrix 
is the network of proteins that provides a structural framework for organizing chromatin and 
facilitating transcription and replication [3]. Included in type I topoisomerases are two 
subfamilies: type IA and type IB.  Type IA topoisomerases include eukaryotic topoisomerase
III and III while type IB topoisomerases include the eukaryotic topoisomerase I [1]. The type 
IB topoisomerases are encoded by the TOP1 gene [11] and are all monomers of mostly 80-100 
kDa in size.  The eukaryotic type IB topoisomerases have a catalytically active fragment of the 
human enzyme bound to DNA.  The human enzyme contains several substructures, which are 
termed core subdomains I, II, III, the linker domain, and the C-terminal domain. The enzyme 
grasps DNA in a ‘C’ clamp and the core subdomains I and II form the upper half of the clamp.  
Subdomain III forms the lower half of the clamp. The linker domain lies between subdomain III 
and the C-terminal domain.  The core subdomains and the C-terminal domains are the ones that 
make most contact with the DNA strand.  Then the DNA is further contacted by two loops from 
subdomains I and III.  Thus, the DNA is entirely enclosed by the protein.  The active site 
tyrosine (Tyr-723) is on the -helix of the C-terminal domain, on the lower half of the clamp [1].
5This enzyme preferentially binds to double-stranded DNA [11]. The DNA is trapped 
between the upper and lower clamps.  If the enzyme were likened to a hand, then the DNA is 
grasped between the fingers and the palm (Figure 1).  The linker domain looks like a thumb
pointing away from the palm.  Once DNA is trapped by the enzyme it is positioned for cleavage. 
Once one strand is cleaved (referred to as the G-strand) then the grip on it loosens allowing the
second strand of DNA (referred to as the T-strand) to rotate about the phosphodiester bond 
opposite the cleavage point, reducing the negative supercoil.  The rest of the G-strand molecule, 
however, remains anchored to the enzyme by the phosphotyrosine bond formed by the active site 
tyrosine with the 5’ end of the cleaved G-strand.  ATP is not necessary for this step because there 
is enough energy stored in the supercoiled duplex for this rotation to take place. The linker is 
positively charged so it helps to attenuate the rotation of DNA by subtly interacting with the 
strand as it rotates.  After the rotation, as the negative supercoil is reduced, the cleaved strand is 
religated [1].
Recently, there have been two camptothecin derivatives registered for cancer treatment:  
irinotecan (CPT-11) for the treatment of colorectal cancer and topotecan (hycamtin) for the 
treatment of ovarian cancer.  These analogs inhibit the religation reaction of the type I 
topoisomerases, especially of the type IB enzymes as these are the ones that preferentially deal 
with double stranded DNA [8 ].  Camptothecins form a ternary complex: topI +DNA +drug [13]. 
Normally, topI-DNA covalent complexes are freely reversible, since the tyrosine-G-strand 
complex is reversible and the energy trapped in the phosphotyrosine bonds can be used to 
religate the G-strand [1].  Upon removal of the enzyme, the DNA returns to its original, 
undamaged state [8].  For the camptothecin derivatives to work and kill the tumor cells the cells 
need to replicate.  Camptothecins convert the topI-DNA complex into a lethal lesion by making 
6the complex an irreversible double strand break (Figure 2).  This occurs when the cleavage 
complex frozen by camptothecin collides with a replication fork, which unwinds DNA for 
replication.  The collision causes the fork to break but the lethal break in DNA occurs.  Thus, the 
religation of the G-strand does not occur and the break endures [5].  The higher the levels of 
topoisomerase I, the higher the frequency of the complexes, and the higher the number of lethal 
DNA lesions.  The irreversible double strand break leads to a frozen cell cycle at the S/G2 phase, 
activation of apoptosis (programmed cell death [9]) pathways, and finally to cell death. Cells 
undergoing S-phase of the cell cycle are found to be much more sensitive to camptothecins than 
those with G1 or G2/M phases. In colon, prostate, ovary and esophagus tumors, elevated 
topoisomerase I levels have been found, leading to the use of camptothecins in treatment of
mainly these forms of cancer [8].
Recent experiments have suggested that CPT-11 and topotecan can also inhibit 
angiogenesis, and this contributes to their anti-tumor activity [8].  Angiogenesis is the process of 
formation of new capillaries around the tumor and the invasion of stroma of surrounding tissue 
by the existing blood vessels. It also includes the development of inter- and intra-cellular spaces 
to form lumina.  In normal tissues, the process of angiogenesis is tightly controlled.  It is a 
delicate balance of factors that promote or inhibit this process.  When tumor cells acquire 
angiogenic properties this balance is lost.  The process is much less inhibited than normally [6].  
This neovascularization has been correlated with increasing invasion and metastases of various 
human tumors.  Experiments in mice show, however, that by increasing the CPT-11 dosage the 
area of angiogenesis in tumors decreases, following a negative curve. At a  dose of 210 mg/kg a 
significant reduction of vessel formation has occurred [8].
7Compared with topotecan, CPT-11 shows a higher antitumor activity in mice when given 
separately and at low dose and the reason for this is the lactone ring of the CPT-11. One of the 
most obvious indications of further clinical development of CPT-11 is colorectal cancer, since 
this type of a tumor is commonly not very sensitive to cytotoxic agents.  In addition to the 
activity of CPT-11 as a single agent in colorectal cancer (overall response ~14%, see Table 1), 
studies also indicate significant antitumor activity in non-small cell lung cancer, small cell lung 
cancer, gastric cancer, malignant lymphoma, acute leukemia, cervical cancer and pancreatic 
cancer.  The activity of single agent topotecan has been described in several tumor types, using 
various means of administration, including ovarian cancer (overall response rate 35 to 38 %, 
Table 1), small-cell lung cancer, non-small cell lung cancer, breast cancer, myelodysplastic 
syndrome, and chronic myelomonocytic leukemia [8].
Table 1. Response Rates of CPT-11 and Topotecan as Single Agents. Table adapted from [8].
Tumor type CPT-11 response % Topotecan response %
Colon 13 (OR), 15 (OR)
Gastric 18-43 (OR)
Pancreatic 9-19 (OR)
Small cell lung cancer 16-47 (OR) 39 (OR), 24 (OR)
Non-small cell lung cancer 16-34 (OR) 13 (OR)




Chronic myelomonocytic leukemia 27 (CR)
Myelodysplastic syndrome 43 (CR)
Abbreviations: OR - overall response; CR - complete response.
Irinotecan is a unique camptothecin derivative.  This drug has clear antitumor activities in 
a variety of human cancers.  Unlike most camptothecins, CPT-11 is a prodrug and requires 
bioactivation by tissue carboxylesterase (CES2) for form active metabolite SN-38 (Figure 3).  
The antitumor activity of SN-38 is at least 100-fold greater than that of irinotecan, but it has a 
8short plasma half-life.  Once in the plasma, irinotecan can be metabolized by cytochrome P450 
3A enzymes to form NCP (7-ethyl- 10-(4-amino-1-piperidino) carbonyloxycamptothecin and 
APC (7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin]. 
Although these two compounds are not directly linked to antitumor activity, their formation 
reduces the amount of irinotecan able to be activated into SN-38.  In aqueous solutions 
irinotecan, APC and NCP undergo a pH-dependant reversible inter-conversion between the ring-
closed lactone form and the ring-opened carboxylate form.  Only the lactone form is believed to 
cross the cell membrane and act as the topoisomerase I poison.  The carboxylate form is not 
active. The SN-38 circulates in the cell. But is eventually deactivated by uridine diphosphate 
glucuronosyltransferases (UGTs) and forms its glucuronide, SN- 38G. Irinotecan and SN-38 are
eventually effluxed out of the cell by transporters like P-glycoprotein (Pgb), breast cancer 
resistant protein (BCRP), and multidrug resistance associated proteins (MRP1 & MRP2) [7].
For some years now irinotecan has been the main drug used in treatment of colon and 
small cell lung cancers.  In addition, it has appreciable activity against a variety of adult and 
pediatric central nervous system tumor xenografts, including high-grade glioma and 
ependymoma [6]. In clinical studies various schedules for administering the drugs were tested.  
In Europe, for CPT-11, the highest planned and actual dose intensities were reached when the 
drug was administered once every three weeks.  In the USA and Japan, the highest dose 
intensities were reached with the once a week schedule.  When it comes to topotecan the general 
consensus around the world is 1.5 mg/m2/day, intravenously delivered over 30 minutes for 5 
consecutive days every three weeks.  The oral administration of topotecan is currently not 
registered [8]. The most common administering schedule for CPT-11 drug is 100-150 mg/m2
over 30 to 90 minute infusion every 4 to 6 weeks, 200 to 350 mg/m2 over 30 or 90 minutes every 
93 or 4 weeks, and 100-150 mg/m2 over 90 minutes weekly infusion. Generally, lower doses 
given over prolonged periods of time are more effective due to a greater production of the active 
SN-38 metabolite [7].
Even though the camptothecin derivatives presently used in treatment of mainly 
colorectal and ovarian cancers have had much success, they have two major limitations: 1) at 
physiological pH they are in equilibrium with their inactive carboxylate form; and 2) the 
camptothecin-trapped cleavage complexes reverse within minutes after drug removal, which 
imposes long and repeated infusions for cancer treatment.  Recently, there also have been many 
cases of resistance to these drugs attributed to various reasons [13].  Topoisomerase I levels in 
tumor cells are frequently reduced when these cells are continuously exposed to topI inhibitors, 
i.e. camptothecins.  There have also been reported point mutations of the topoisomerase I gene 
and reduced drug accumulation caused by overexpression of transporters that efflux the drugs 
out of the cell. These include the MDR-1, P-glycoprotein, BCRP and other transporters. In 
addition, increased SN-38 inactivation by UGTs leads to reduced drug levels of the active 
compound and increases the resistance to camptothecins.  Chemoresistance might also be caused 
by the activation of nuclear factor-B (NF-B), a transcription factor, and its activation is caused 
by administration of camptothecins.  The activation of NF-B leads to suppression of cell death 
normally caused by the topoisomerase I poisons.  CPT administrations also activate another 
important chemical that adds to the resistance against these drugs: cyclin dependent kinase 
inhibitor (CD-K1).  This molecule arrests the cell in the G1 or G2 phase of the cell cycle. As 
mentioned earlier, mainly the S-phase tumor cells are sensitive to camptothecins; thus, the arrest 
caused by CD-K1 leads to increased resistance against the drugs [8]. 
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Another problem that camptothecins pose is their toxicity. For irinotecan life-threatening 
diarrhea is the main toxicity associated with repeated dosing, although neutropenia (abnormal 
decrease in the number of neutrophils in the blood [9]) has also been reported in several clinical 
trials. The diarrhea is unpredictable and the incidence of severe diarrhea ranges from 11 to 
36.4% in colorectal cancer patients.  The severity of diarrhea is thought to be caused mainly by 
the extent of glucuronidation of SN-38.  Since SN- 38G has a longer half-life than SN-38 and is 
more abundant than SN-38, there is sufficient time for it to accumulate in large intestinal 
epithelial cells where the enteric bacteria deconjugate it causing local damage and inducing 
diarrhea [7].  However, the once every three-weeks schedule seems to suggest a lower non-
hematological toxicity. Still, though, cumulative behavior for leucopenia (a decrease in the 
number of white blood cells in the blood [9]) and delayed diarrhea has been reported.  CPT-11 
related diarrhea may be divided in an acute and a delayed form.  The acute form appears during 
or within several hours after infusion. Delayed diarrhea is severe and unpredictable, present at 
all dose levels and increasing in intensity and frequency at higher dose levels.  The exact 
mechanism of this type of diarrhea is not known, but it has been suggested that an abnormal 
intestinal ion transport may be responsible.  This is probably related to altered epithelial 
intestinal cells.  The average time of onset of delayed diarrhea is two to seven days.  Sometimes, 
taste perversions, elevated hepatic transaminases or fatigue may occur.  Alopecia (or baldness
[9]) is common, especially at higher dose levels.  In CPT-11 treated lung cancer patients, 
pneumonitis has been found much more frequently than in patients with other tumors.  At all 
dose-levels of CPT-11, gastrointestinal cramps, nausea, vomiting, asthenia and diaphoresis can 
be observed.  At higher dose levels salivation, anorexia, visual accommodation disturbances and 
lacrimation (abnormal secretion of tears [9]) were seen.  For topotecan, the dose-limiting 
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toxicities are neutropenia and thrombocytopenia (an abnormal decrease in the number of 
platelets in the blood [9]). Severe thrombocytopenia is also a rare side effect after CPT-11 
therapy.  After topotecan or CPT-11 administration anemia is frequently observed, but rarely is 
clinically significant.  At higher dose-levels of topotecan mucositis and late diarrhea may 
become dose-limiting toxicities.  However, the non-hematological side effects for topotecan are 
rare, in contrast to CPT-11 [8].
Due to resistance to and the adverse effects of the drugs new approaches are being 
developed to improve the current camptothecin derivatives.  One way to improve the therapeutic 
potential of topoisomerase I poisons is by inhibiting NF-B.  Normally, complexes of NF-B 
reside in an inactive state within the cytoplasm bound to the inhibitory IB protein.  Following 
stimulus from the cell, activation of IB kinases leads to phosphorylation of the inhibitory IB 
protein, which is then immediately degradated by the 26S proteasome.  Thus, the NF-B units 
are free to bind to nuclear DNA and activate transcription of specific genes that inhibit apoptosis. 
However, this process also occurs after exposure to topoisomerase inhibitors, like the 
camptothecins, which increases tumor cells’ resistance to these drugs.  To ensure that the IB 
proteins are degraded by 26S proteasomes, they are modified in the cell by the addition of 
multiple monomers of ubiquitin – a polypeptide consisting of 76 amino acids.  However, if 
proteasome inhibitor, such as MG-132 or PS-341, is used on tumor cells, it does not come to the 
degradation of IB and the NF-B is thus not activated.  But the proteasome inhibitors cannot be 
used before the treatment with a camptothecin, because then the apoptosis is actually even lower 
than when only camptothecin is used – cell survival is enhanced.  Studies suggest that this is due 
to the fact that many other factors, besides NF-B, actually cause the cell to undergo apoptosis. 
Apoptosis induced by topoisomerase inhibitors is actually NF-B independent.  It seems that the 
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proteasome inhibition process functions as a downstream effector of apoptosis following DNA 
damage caused by camptothecins. Camptothecin treatment of non-small cell lung cancer cells 
followed by proteasome inhibitor treatment significantly increases the population of apoptotic 
cells (sub-G1 population).  The apoptosis occurs either in late S-G2 phase or possibly when 
exiting from mitosis, resulting in cells with sub-G1 DNA content. SN-38 treatment followed by 
PS-341 treatment leads to tumor cells undergoing apoptosis at a rate approximately 2 fold higher 
than with SN-38 alone (Figure 4).  Thus, the therapeutic potential of camptothecins can be 
improved and resistance to these drugs can be lowered by the post treatment with proteasome 
inhibitors [12].
Another way to improve the efficacy and especially the selectivity of camptothecins is 
with the use of sequence-specific ligands.  Sequence specific modulation of gene expression can 
be achieved by oligonucleotides that bind to DNA by the triplex formation.  These have been 
used as sequence-specific ligands to guide recombination or DNA cleavage in various 
experiments.  When bound to specific chemical agents, triplex-forming oligonucleotides (TFOs)
can deliver the agent to a specific sequence on the DNA for modification by the chemical.  The 
oligonucleotide acts as a carrier molecule and its specific binding in the major groove of the 
double helix anchors the chemical agent at the triplex site specific for the TFO used.  Thus, the 
use of topoisomerase I poisons with the TFOs offers a more efficient system to induce a 
sequence-selective DNA damage by cellular enzymes [11].
Normally, topoisomerase I enzymes have a low degree of site selectivity – it has been 
suggested that they mostly recognize DNA structural features.  Camptothecins, however, have a 
two base sequence that they select for to stabilize the lethal cleavage: TG (the arrow denotes the 
site of cleavage by the enzyme).  Two main approaches have been explored to enhance the 
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efficacy and selectivity of topoisomerase I inhibitors, i.e. camptothecins: 1) the delivery of these 
agents specifically to tumor cells by using antibodies or peptides or liposomes or viruses; and 2) 
their targeting to specific genes by attaching them to sequence-specific TFOs in order to induce a 
sequence-specific DNA damage.  The newest strategy is to target DNA cleavage by these drugs 
to specific sites on the genome upon their linkage to a sequence-specific DNA ligand.  The TFOs
bear the camptothecin at their 3’ end and stimulate the DNA cleavage by the enzyme only on the 
3’-side of the triplex where the drug is anchored, and decrease it at the other characteristic sites 
of the drug.  Binding of the TFO to this DNA site brings the poison in such a position that it 
inhibits the religation of the topI cleavage complex provided that the topI cleavage site is located 
at the appropriate position with respect to the triple-helical structure.  In the future, the ability of 
TFO-conjugates to target topoisomerase cleavage to specific genes could provide a new model 
for the development of more specific chemotherapeutic agents and sequence-selective DNA
damaging agents.  If, for example, it is known that a certain type of cancer has a specific 
sequence activated which is dormant in healthy cells than the TFO-conjugate can be made to 
bind to that sequence and cleave it, causing lethal lesions in these tumor cells [11].
At this time, clinical experiments are being performed on a new line of topI inhibitors, 
those of non-camptothecin origin, because camptothecins’ efficacy continues to decrease as more 
resistance to them develops.  Polycyclic aromatics represent the most promising topI inhibitors 
for clinical development as anticancer agents.  Indolocarbazoles are the most advanced class of 
non-camptothecin polycyclic drugs in terms of chemotype, clinical development and structure-
activity.  Unlike camptothecins, indolocarbazoles intercalate into DNA and bind to triplex DNA. 
They also inhibit the religation step of the topoisomerase I process, but the drugs are more 
potent.  They stabilize cleavage complexes at sites bearing T, A, or C at the 3’-end of the cleaved 
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DNA and G on the 5’-side of the cleavage.  There is still some resistance to indolocarbazoles
(the drugs share a common cellular efflux system with camptothecins) but it is lower than that 
for camptothecins, because these drugs may target other cellular pathways besides topI.  There 
are various kinds of indolocarbazoles. NB-506 is one that shows remarkable activity against 
experimental human cancer xenografts, including colon and lung cancers, while having a low 
toxicity profile.  It is effective in regressing tightly staged tumors when dosed consecutively for 
10 days.  J-107088, another indolocarbazole, shows potent activity against lung cancer and 
prostate cancer. It also may be active in childhood and adult malignant brain tumors.  Compared 
with CPT-11 and topotecan, it clears less rapidly out of the system, which puts it as a future 
rational choice for CNS tumors, particularly in patients treated with anticonvulsants, which cause 
glucuronidation (or inactivation) of CPT-11 and topotecan [13].
Another line of non-camptothecin drugs are the minor groove binding topI inhibitors.  Of 
these, benzimidazoles and ecteinascidin 743 deserve most attention.  Benzimidazoles bind to 
AT-rich sequences of the minor groove of DNA, causing widening of the minor groove.  They 
trap topI complexes and induce them to cause lethal cleavages  in the minor groove.  
Camptothecin-resistant human lymphoblast cells are only 4-5-fold cross-resistant to these drugs.  
Ecteinascidin 743 is a potent topI inhibitor from the Caribbean tunicate (“sea squirt”).  It shows 
remarkable activity in soft tissue sarcomas, and solid tumors including ovarian cancers.  The 
drug traps topI-DNA cleavage complexes in vitro and in cancer cells but it seems to act by a 
unique mechanism of action: poisoning of transcription-coupled nucleotide excision repair [13].
Topoisomerase I has been proven to be an effective target in a wide range of 
malignancies, and substantial clinical activity has been seen with the use of camptothecins.  The 
many biochemical and pharmacological investigations provide a clear and almost complete 
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mechanism of action of this class of agents.  Our understanding of topI biochemistry and its 
importance will enable us to improve the current camptothecins in use and develop new topI 
inhibitors that are more efficient and less toxic and might possibly replace the current 
camptothecins on the market. However, continued successful development of topoisomerase I-
targeting drugs requires further investigation and more clinical research.  There are still some 
obscurities even about the structure and mechanism of action of camptothecins, due their 
relatively new status in clinical treatments.  Future pharmacogenetic studies will provide us more 
knowledge on these issues.  This should finally result in individualized dosing of topI inhibitors 
that gives an adequate and less toxic therapy for the individual cancer patient.  In addition, 
combination studies with other anticancer agents with different cellular targets are also ongoing 
and might eventually lead to higher response rates when compared to camptothecin treatment 
alone [8].
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